The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis

Abstract

<b><i>Background:</i></b> Interleukin (IL) inhibitors have made <i>completely cleared skin</i> achievable for many patients with moderate to severe psoriasis in clinical trial settings. Few observational studies assess treatment response in accordance with treatment goals in guidelines. <b><i>Objectives:</i></b> The aim of the study was to analyze the treatment response of IL-17/IL-23 inhibitors in clinical practice and the proportions of patients that reach the treatment target of the Psoriasis Area and Severity Index (PASI) < 3 and the Dermatology Life Quality Index (DLQI) ≤5. <b><i>Methods:</i></b> A longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Psoriasis, PsoReg. Patients using IL-17/IL-23 inhibitors with assessments of PASI, DLQI, and EQ-5D before (maximum 6 months) and after (3–12 months) initiation of IL-17/IL-23 were included. <b><i>Results:</i></b> In total, 333 patients using IL-17/IL-23 inhibitors were included. Eighty percent (<i>n</i> = 266) received IL-17 inhibitors, and 20% (<i>n</i> = 67) received IL-23 inhibitors. Sixty-six percent of patients reached both PASI <3 and DLQI ≤5, 23% reached one target, and 11% reached none. The mean (SD) PASI, DLQI, and EQ-5D improvements were 6.75 (6.99), 7.14 (7.97), and 0.126 (0.296), respectively. There was no statistically significant difference in outcomes between IL-17 and IL-23 inhibitor treatment groups. <b><i>Conclusions:</i></b> IL-17/IL-23 inhibitors are effective in clinical practice, but there is still an unmet therapeutic need in moderate to severe psoriasis.

Ameliorated Skin Inflammation through the Synergistic Effect of Gold Nanorod–Dexamethasone and Photothermal Therapy

“…The mice received daily topical treatment with IMQ cream (62.5 mg) on their dorsal skin. The mice were randomly assigned to the following groups: (1) Control, (2) IMQ, (3) IMQ + 0.2 μg of AuNR-DX, (4) IMQ + 0.2 μg of AuNR-DX + 808 nm laser (promptly; 0 h), (5) Korea) was irradiated for 30 s. Topical administration of IMQ was performed on the dorsal skin, and AuNR-DX or DX was applied to the mouse skin for 7 consecutive days. Every 24 h, the PASI of the mouse skin was assessed and the skin thickness was measured using a dial thickness gauge (Mitutoyo Co.).…”

“…3,4 While these inhibitors are efficacious in clinical settings, an unmet therapeutic need persists for moderate to severe psoriasis stages. 5 Additionally, we currently lack a definitive cure for psoriasis.…”

“…This skin condition is characterized by red spots and silvery scales, typically requiring long-term treatment owing to its inherent chronic, recurrent, and immune-related nature . Recent research addressing various aspects of psoriasis treatment has led to the invention of drugs, such as IL-17 and/or IL-23 inhibitors, for treating psoriasis. , While these inhibitors are efficacious in clinical settings, an unmet therapeutic need persists for moderate to severe psoriasis stages . Additionally, we currently lack a definitive cure for psoriasis.…”